ArticleThe Journal of biological chemistry2019
Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding.
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 51 citations in OpenAlex.
- Sialic acids modulate immune responses in cancer: Therapeutic opportunities.The Journal of biological chemistry · 2026Review
- CAR Treg therapies for neurodegenerative diseases.iScience · 2026Review
- Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression.Frontiers in immunology · 2026Article
- Structure, function, and implications of fucosyltransferases in health and disease.Nature communications · 2025Review
- Enforced E-selectin ligand installation enhances homing and efficacy of adoptively transferred T cells.bioRxiv : the preprint server for biology · 2025Article
- Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects.Frontiers in immunology · 2025Review
- Genetics of glycosylation in mammalian development and disease.Nature reviews. Genetics · 2024Review
- Glycoengineering in antigen-specific immunotherapies.Current opinion in chemical biology · 2024Review
- Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.Seminars in immunopathology · 2024Review
- Chemical immunology: Recent advances in tool development and applications.Cell chemical biology · 2024Review
- Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow.Leukemia · 2024Article
- Microengineered In Vitro Assays for Screening and Sorting Manufactured Therapeutic T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.Nature reviews. Clinical oncology · 2024Review
- Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies.Biotechnology advances · 2023Review
- CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working.Drug design, development and therapy · 2023Review
- Tinker, tailor, soldier, cell: the role of C-type lectins in the defense and promotion of disease.Protein & cell · 2023Review
- The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.Frontiers in immunology · 2023Review
- Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics.Theranostics · 2023Review
- Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.International journal of molecular sciences · 2022Review
- Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma.Genes & development · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Tissue colonization (homing) by blood-borne cells critically hinges on the ability of the cells to adhere to vascular endothelium with sufficient strength to overcome prevailing hemodynamic shear stress. These adhesive interactions are most effectively engendered via binding of the endothelial lectin E-selectin (CD62E) to its cognate ligand, sialyl Lewis-X (sLe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.